Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Tuan

Sports Medicine Decatur, IL Medical Doctor

NPI 1477520955 CMS profile 248468

304 W Hay St Ste 218, Decatur, IL 62526

Open in the dashboard

General payments

$12,725

114 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Tuan of Decatur, IL is reported in the CMS Open Payments database as having received $12,725 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $147 4
2024 General $1,526 26
2023 General $2,803 26
2022 General $3,357 25
2021 General $3,089 21
2020 General $217 3
2019 General $1,586 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Tuan
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Kenneth Tuan were reported at $147. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Kenneth Tuan Sports Medicine median Middle half National median
2019 $1,586 $1,176 $199–$4,249 $163
2020 $217 $708 $96–$2,890 $114
2021 $3,089 $1,213 $152–$3,994 $132
2022 $3,357 $1,230 $159–$3,998 $149
2023 $2,803 $584 $146–$2,836 $160
2024 $1,526 $628 $163–$3,168 $164
2025 $147 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $8,511 65 payments
  2. Wardlow Enterprises $2,234 17 payments
  3. Zimmer Biomet Holdings, Inc. $1,096 16 payments
  4. Stryker Corporation $766 11 payments
  5. DePuy Synthes Sales Inc. $35 1 payment
  6. KCI USA, Inc $25 1 payment
  7. Orthofix Medical, Inc. $22 1 payment
  8. Prism Medical $19 1 payment
  9. Ferring Pharmaceuticals Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $6,376 31 payments
  2. Education $3,451 3 payments
  3. Food and Beverage $2,898 80 payments
Products named General payments · program years 2019–2025
  1. Comprehensive Primary Stem $678 8 payments
  2. MAKO Knees, Hips $327 4 payments
  3. VERASENSE $147 1 payment
  4. MAKO Knees, Hips $147 1 payment
  5. ROSA Knees $130 1 payment
  6. GAMMA $125 2 payments
  7. ROSA Knees $107 4 payments
  8. Knees Product Portfolio $64 1 payment
  9. A.L.P.S. $60 1 payment
  10. Comprehensive Shoulder $57 1 payment
  11. Other $385 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

260

Median for Orthopedic Surgery: 203

Drug cost

$2,053

Median for Orthopedic Surgery: $1,433

Branded share of claims

67.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 146 $1,619
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 29 $163
Famotidine Generic 30 $150
Tramadol Hcl Generic 43 $115
Amoxicillin Generic 12 $5

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$131,997

Of which drugs: $2,054

Medicare patients

292

Average age 76

Services billed

8,746

199 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Ischemic heart disease 43%
Diabetes 27%
Depression 27%
Chronic kidney disease 26%
Atrial fibrillation 25%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 56 7,081 $719
Injection, methylprednisolone acetate, 80 mg J1040 Office 26 29 $192

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record